Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg？, a pegfilgrastim biosimilar in healthy subjects

DOI: 10.1002/prp2.503

Keywords: biosimilar, filgrastim, myelosuppressive chemotherapy, Neulasta, neutropenia, oncology, pegfilgrastim, Pelmeg, supportive care

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text